ANI Pharmaceuticals ANIP Generics and Other — Contingent consideration fair value adjustment

Other segment segments

Rare Disease and Brands

$0—

Similar metrics at other companies

INSMContingent consideration fair value adjustment

-$46.96M-357%

TTEKContingent consideration – fair value adjustments

$58K-97.0%

FOURChange in fair value of contingent consideration

$0+100%

RUMChange In Fair Value Of Contingent Consideration

$338.59K—

IOSPContingent Consideration Adjustment To Fair Value

-$4.7M-771%

AWIChange in fair value of contingent consideration

$0-100%

Other financials

Income statement

See full

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

See full

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

See full

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

See full

Market cap$1.89B+18.3%

Enterprise value$1.88B+5.8%

P/E20.5×—

P/S2×-0.3×

Profitability

See full

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

See full

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's generics and other — contingent consideration fair value adjustment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ANI Pharmaceuticals's generics and other — contingent consideration fair value adjustment?: ANI Pharmaceuticals (ANIP) reported generics and other — contingent consideration fair value adjustment of $0 in Q1 2026.
What does generics and other — contingent consideration fair value adjustment mean?: Reflects changes in the estimated fair value of liabilities related to earn-outs or future payments for acquisitions within the generics segment. Fluctuations in this metric indicate changes in management's expectations regarding the future performance of acquired assets or businesses.